Comparing Efficacy and Safety of Enlituo® Versus Erbitux® Plus FOLFOX in Locally Advanced/Metastatic Colorectal Cancer With RAS/BRAF Wild-type and MSS/pMMR Status.

This is a randomized, double-blind, phase III clinical trial. The study aims to demonstrate that the treatment regimen of Enlituo® plus FOLFOX is equivalent to that of Erbitux® plus FOLFOX in participants with RAS/BRAF wild-type and MSS/pMMR locally advanced/metastatic colorectal cancer. Enrolled participants will be stratified according to ECOG performance status (0 vs. 1) and primary tumor location (left-sided or right-sided colon) and randomly assigned in a 1:1 ratio to either the experimental group (Enlituo® + FOLFOX) or the control group (Erbitux® + FOLFOX). Participants will: * Receiv

Trial Details

NCT ID
NCT07595276
Phase
PHASE3
Sponsor
Taizhou Mabtech Pharmaceutical Co.,Ltd
Status
RECRUITING
Cancer Type
Rectal Cancer Colorectal Cancer
Interventions
  • Enlituo®
  • Erbitux®
Locations (sample)
  • Guangzhou, China|23.11667,113.25

Key Eligibility Criteria

  • Voluntarily participate in the study and sign the informed consent form.
  • Aged 18 years or older.
  • Participants with histologically and/or cytologically confirmed locally advanced/metastatic colorectal cancer.
  • Have at least one evaluable or measurable tumor target lesion (RECIST v1.1). Lesions that have received previous local therapy or locoregional ther…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Rectal Cancer Colorectal Cancer Trials on Trialify →